Imatinib Mesylate Attenuates Myocardial Remodeling Through Inhibition of Platelet-Derived Growth Factor and Transforming Growth Factor Activation in a Rat Model of Hypertension

被引:20
|
作者
Jang, Sung-Won [1 ]
Ihm, Sang-Hyun [1 ]
Choo, Eun-Ho [1 ]
Kim, Ok-Ran [1 ]
Chang, Kiyuk [1 ]
Park, Chan-Seok [1 ]
Kim, Hee-Yeol [1 ]
Seung, Ki-Bae [1 ]
机构
[1] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Cardiol, Seoul, South Korea
关键词
imatinib; platelet-derived growth factor; rats; inbred SHR; transforming growth factor beta; ventricular remodeling; CHRONIC MYELOID-LEUKEMIA; MOLECULAR-MECHANISMS; TRANSGENIC MICE; TGF-BETA; DERMAL FIBROBLASTS; PULMONARY-FIBROSIS; HEART-FAILURE; FOLLOW-UP; FACTOR-C; HYPERTROPHY;
D O I
10.1161/HYPERTENSIONAHA.113.01866
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Imatinib mesylate is a specific tyrosine kinase inhibitor that may block the platelet-derived growth factor and transforming growth factor pathways. These pathways are known to provoke fibroblast activation. We evaluated whether imatinib, by inhibiting these pathways, prevents diastolic dysfunction and attenuates myocardial remodeling using spontaneously hypertensive rats (SHRs). Eight-week-old male SHRs were randomly assigned to either imatinib treatment group (30 mg/kg per day; n=10; SHR-I) or hypertensive control group (distilled water, n=10; SHR-C). Wistar-Kyoto rats were used as normal controls (n=10). At 16 weeks, all rats underwent hemodynamic studies and Doppler echocardiography and then were euthanized. Their hearts were extracted for histopathologic, immunoblotting, and quantitative reverse transcriptase polymerase chain reaction analyses. Although imatinib did not affect blood pressure, it markedly reduced perivascular and interstitial fibrosis in the hearts of SHR. Echocardiogram showed that imatinib significantly reduced the left ventricular wall thickness (septal/posterior wall; SHR-C versus SHR-I, 18 +/- 1/19 +/- 2 versus 15 +/- 1/15 +/- 1 mm; P<0.001) and increased the E/A ratio (SHR-C versus SHR-I, 1.59 +/- 0.11 versus 1.84 +/- 0.16; P=0.001). Also, imatinib significantly reduced the mRNA expression of collagen type I, III, and platelet-derived growth factor receptor- phosphorylation in the hearts of SHR. In addition, imatinib reduced collagen production by inhibiting the phosphorylation of c-abl and platelet-derived growth factor receptor- in rat cardiac fibroblasts. In conclusion, these results suggest that imatinib could attenuate myocardial remodeling and improve left ventricular diastolic dysfunction in a hypertensive rat model by affecting platelet-derived growth factor and transforming growth factor-1 pathway without the blood pressure-lowering effect.
引用
收藏
页码:1228 / 1234
页数:7
相关论文
共 50 条
  • [1] Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor
    Holdhoff, M
    Kreuzer, KA
    Appelt, C
    Scholz, R
    Na, IK
    Hildebrandt, B
    Riess, H
    Jordan, A
    Schmidt, CA
    Van Etten, RA
    Dörken, B
    le Coutre, P
    BLOOD CELLS MOLECULES AND DISEASES, 2005, 34 (02) : 181 - 185
  • [2] Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer
    Mathew, P
    Fidler, IJ
    Logothetis, CJ
    SEMINARS IN ONCOLOGY, 2004, 31 (02) : 24 - 29
  • [3] Imatinib attenuates cardiac fibrosis by inhibiting platelet-derived growth factor receptors activation in isoproterenol induced model
    Wang, Le-Xun
    Yang, Xiao
    Yue, Yuan
    Fan, Tian
    Hou, Jian
    Chen, Guang-Xian
    Liang, Meng-Ya
    Wu, Zhong-Kai
    PLOS ONE, 2017, 12 (06):
  • [4] Platelet-derived growth factor involvement in myocardial remodeling following infarction
    Zhao, Wenyuan
    Zhao, Tieqiang
    Huang, Valerie
    Chen, Yuanjian
    Ahokas, Robert A.
    Sun, Yao
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2011, 51 (05) : 830 - 838
  • [5] Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis
    Abdollahi, A
    Li, ML
    Ping, G
    Plathow, C
    Domhan, S
    Kiessling, F
    Lee, LB
    McMahon, G
    Gröne, HJ
    Lipson, KE
    Huber, PE
    JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (06): : 925 - 935
  • [6] In vivo activation of rat aortic platelet-derived growth factor and epidermal growth factor receptors by angiotensin II and hypertension
    Kim, S
    Zhan, YM
    Izumi, Y
    Yasumoto, H
    Yano, M
    Iwao, H
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (12) : 2539 - 2545
  • [7] Targeting platelet-derived growth factor with imatinib in idiopathic pulmonary arterial hypertension
    Antoniu, Sabina A.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2009, 13 (03) : 381 - 383
  • [8] Platelet-derived growth factor (PDGF) [Platelet-Derived Growth Factor (PDGF)]
    Eitner F.
    Floege J.
    Der Nephrologe, 2008, 3 (5): : 418 - 419
  • [9] Platelet-derived growth factor B attenuates lethal sepsis through inhibition of inflammatory responses
    Wang, Min
    Wei, Jilou
    Shang, Futai
    Zang, Kui
    Ji, Ting
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 75
  • [10] PLATELET-DERIVED TRANSFORMING GROWTH FACTOR-BETA
    ASSOIAN, RK
    KOMORIYA, A
    MEYERS, CA
    SPORN, MB
    FEDERATION PROCEEDINGS, 1983, 42 (07) : 1831 - 1831